ONCRライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 12月 2023 @ 04:55):

Stats
本日の出来高	135 947
平均出来高	108 675
時価総額	3.29M
EPS	$0 ( 2024-03-21 )
次の収益日	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0362
ATR14	$0.00400 (3.17%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-06	Shea Brian J.	Sell	0	Common Stock
2023-06-06	Shea Brian J.	Sell	15 000	Employee Stock Option (right to buy)
2023-06-06	Shea Brian J.	Sell	3 744	Employee Stock Option (right to buy)
2023-06-06	Shea Brian J.	Sell	14 700	Employee Stock Option (right to buy)
2023-06-06	Shea Brian J.	Sell	19 100	Employee Stock Option (right to buy)

INSIDER POWER
-40.11
Last 97 transactions
Buy: 2 441 000 \| Sell: 694 654

ボリューム相関

長: 0.41 (neutral)

短: 0.27 (neutral)

Signal:(89.911) Neutral

Oncorus, Inc. 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Oncorus, Inc. 相関 - 通貨/商品

0.31
( neutral )

0.17
( neutral )

0.00
( neutral )

0.14
( neutral )

0.87
( strong )

-0.28
( neutral )

Oncorus, Inc. 財務諸表

Annual	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-3.02

FY	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-3.02

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-2.56

FY	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-9.35

Financial Reports:

No articles found.

Oncorus, Inc.

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.